Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV clinical trial of Repatha® (evolocumab), will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback